These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37280569)

  • 1. The indirect impacts of nonpharmacological COVID-19 control measures on other infectious diseases in Yinchuan, Northwest China: a time series study.
    Liu W; Wang R; Li Y; Zhao S; Chen Y; Zhao Y
    BMC Public Health; 2023 Jun; 23(1):1089. PubMed ID: 37280569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: A large population-based observational study.
    Xiao J; Dai J; Hu J; Liu T; Gong D; Li X; Kang M; Zhou Y; Li Y; Quan Y; He G; Zhong R; Zhu Z; Huang Q; Zhang Y; Huang J; Du Q; Li Y; Song T; Hu W; Zhong H; Ma W
    Lancet Reg Health West Pac; 2021 Dec; 17():100282. PubMed ID: 34611630
    [No Abstract]   [Full Text] [Related]  

  • 3. Temporal shifts in 24 notifiable infectious diseases in China before and during the COVID-19 pandemic.
    Li K; Rui J; Song W; Luo L; Zhao Y; Qu H; Liu H; Wei H; Zhang R; Abudunaibi B; Wang Y; Zhou Z; Xiang T; Chen T
    Nat Commun; 2024 May; 15(1):3891. PubMed ID: 38719858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence and Variation of the Indirect Effects of COVID-19 Restrictions on the Spectrum of Notifiable Infectious Diseases in China: Analysis of National Surveillance Among Children and Adolescents From 2018 to 2021.
    Chen L; Wang L; Xing Y; Xie J; Su B; Geng M; Ren X; Zhang Y; Liu J; Ma T; Chen M; Miller JE; Dong Y; Song Y; Ma J; Sawyer S
    JMIR Public Health Surveill; 2024 May; 10():e47626. PubMed ID: 38748469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in notifiable infectious disease incidence in China during the COVID-19 pandemic.
    Geng MJ; Zhang HY; Yu LJ; Lv CL; Wang T; Che TL; Xu Q; Jiang BG; Chen JJ; Hay SI; Li ZJ; Gao GF; Wang LP; Yang Y; Fang LQ; Liu W
    Nat Commun; 2021 Nov; 12(1):6923. PubMed ID: 34836947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in Incidence of Notifiable Infectious Diseases in China Under the Prevention and Control Measures of COVID-19.
    Chen B; Wang M; Huang X; Xie M; Pan L; Liu H; Liu Z; Zhou P
    Front Public Health; 2021; 9():728768. PubMed ID: 34722440
    [No Abstract]   [Full Text] [Related]  

  • 7. Trends and disparities in 44 national notifiable infectious diseases in China: An analysis of national surveillance data from 2010 to 2019.
    Du M; Wang R; Yuan J; Lv X; Yan W; Liu Q; Qin C; Xiang N; Zhu L; Liang W; Liu M; Liu J
    J Med Virol; 2023 Jan; 95(1):e28353. PubMed ID: 36443103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of COVID-19 on the epidemiology of non-airborne/droplet-transmitted notifiable infectious diseases in Taiwan: A descriptive study.
    Hung SH; Lin WT; Wang JH; Lai CC
    J Infect Public Health; 2022 Sep; 15(9):1001-1005. PubMed ID: 35981407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of anti-COVID-19 nonpharmaceutical interventions on hand, foot, and mouth disease-A spatiotemporal perspective in Xi'an, northwestern China.
    Shen L; Sun M; Song S; Hu Q; Wang N; Ou G; Guo Z; Du J; Shao Z; Bai Y; Liu K
    J Med Virol; 2022 Jul; 94(7):3121-3132. PubMed ID: 35277880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrupted time series analysis using the ARIMA model of the impact of COVID-19 on the incidence rate of notifiable communicable diseases in China.
    Zhou Q; Hu J; Hu W; Li H; Lin GZ
    BMC Infect Dis; 2023 Jun; 23(1):375. PubMed ID: 37316780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-pharmaceutical interventions for COVID-19 reduced the incidence of infectious diseases: a controlled interrupted time-series study.
    Zhang W; Wu Y; Wen B; Zhang Y; Wang Y; Yin W; Sun S; Wei X; Sun H; Zhang Z; Li S; Guo Y
    Infect Dis Poverty; 2023 Mar; 12(1):15. PubMed ID: 36895021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of different levels of non-pharmaceutical interventions on hand, foot and mouth disease in Guangzhou, China.
    Wu K; Ma X; Liu H; Zheng J; Zhou R; Yuan Z; Huang Z; Zhong Q; Huang Y; Zhang Z; Wu X
    BMC Public Health; 2022 Dec; 22(1):2398. PubMed ID: 36539790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term variations of urban-Rural disparities in infectious disease burden of over 8.44 million children, adolescents, and youth in China from 2013 to 2021: An observational study.
    Chen L; Xing Y; Zhang Y; Xie J; Su B; Jiang J; Geng M; Ren X; Guo T; Yuan W; Ma Q; Chen M; Cui M; Liu J; Song Y; Wang L; Dong Y; Ma J
    PLoS Med; 2024 Apr; 21(4):e1004374. PubMed ID: 38607981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate and long-term changes in infectious diseases in China at the "First-level-response", "Normalized-control" and "Dynamic-COVID-zero" stages from 2020 to 2022: a multistage interrupted-time-series-analysis.
    Shi T; Zhang X; Meng L; Li D; Jin N; Zhao X; Zheng H; Wang T; Li R; Ren X
    BMC Public Health; 2023 Jul; 23(1):1381. PubMed ID: 37464368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the coronavirus disease 2019 epidemic on notifiable infectious diseases in Taiwan: A database analysis.
    Lai CC; Chen SY; Yen MY; Lee PI; Ko WC; Hsueh PR
    Travel Med Infect Dis; 2021; 40():101997. PubMed ID: 33640476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden changes in notifiable infectious diseases in Taiwan during the COVID-19 pandemic.
    Yang YF; Chen YM; Chen SY; Chiu PH; Chen SC
    PeerJ; 2024; 12():e18048. PubMed ID: 39267943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and trends of 17 notifiable bacterial infectious diseases in China, 2004-2019.
    Zhu Y; Lin S; Dong S; Zhang C; Shi L; Ren X; Li Z; Wang L; Fang L
    BMC Infect Dis; 2023 May; 23(1):273. PubMed ID: 37131164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notifiable diseases after implementation of COVID-19 public health prevention measures in Central Queensland, Australia.
    Adegbija O; Walker J; Smoll N; Khan A; Graham J; Khandaker G
    Commun Dis Intell (2018); 2021 Feb; 45():. PubMed ID: 33632091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the coronavirus disease 2019 pandemic on the diversity of notifiable infectious diseases: a case study in Shanghai, China.
    Zhang Y; Feng W
    PeerJ; 2024; 12():e17124. PubMed ID: 38495754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of national COVID-19 restrictions on incidence of notifiable communicable diseases in England: an interrupted time series analysis.
    Nash K; Lai J; Sandhu K; Chandan JS; Shantikumar S; Ogunlayi F; Coleman PC
    BMC Public Health; 2022 Dec; 22(1):2318. PubMed ID: 36510205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.